192944-50-6Relevant articles and documents
HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR
-
Paragraph 0284; 0285;0286;0287; 0288, (2013/04/10)
A novel heterocyclic compound or a salt thereof useful for selectively inhibiting the degradation of p27Kip1 is provided. The compound or the salt thereof is represented by the following formula (1): wherein A represents an alkyl group, a cycloalkyl group, an aryl group or a heterocyclic group, the group A may have a substituent; the ring B represents a 5- to 8-membered monocyclic heterocyclic ring or a condensed ring containing the monocyclic heterocyclic ring, the ring B may have a substituent; the ring C represents an aromatic ring, the ring C may have a substituent; L represents a linker comprising a main chain having 3 to 5 atoms selected from the group consisting of a carbon atom, a nitrogen atom, an oxygen atom and a sulfur atom, wherein at least one atom in the main chain is a hetero atom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, the linker L may have a substituent; and n is 0 or 1.
Integrin antagonists
-
, (2008/06/13)
This invention relates to novel heterocycles which are useful as antagonists of the αvβ3 integrin, the α2bβ3 integrin, and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.
Disubstituted indazoles as potent antagonists of the integrin α(v)β3
Batt, Douglas G.,Harlow, Patricia P.,Barbera, Frank A.,Spitz, Susan M.,Wexler, Ruth R.,Jadhav, Prabhakar K.,Petraitis, Joseph J.,Houghton, Gregory C.,Modi, Dilip P.,Cain, Gary A.,Corjay, Martha H.,Mousa, Shaker A.,Bouchard, Peter J.,Forsythe, Mark S.
, p. 41 - 58 (2007/10/03)
A new series of indazole-containing α(v)β3 integrin antagonists is described. Starting with lead compound 18a, variations in a number of structural features were explored with respect to inhibition of the binding of β3-transfected 29
